• Something wrong with this record ?

Caveolin-1 in oncogenic metabolic symbiosis

M. Raudenska, J. Gumulec, J. Balvan, M. Masarik

. 2020 ; 147 (7) : 1793-1807. [pub] 20200421

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

Persistent link   https://www.medvik.cz/link/bmc21020055

Metabolic phenotypes of cancer cells are heterogeneous and flexible as a tumor mass is a hurriedly evolving system capable of constant adaptation to oxygen and nutrient availability. The exact type of cancer metabolism arises from the combined effects of factors intrinsic to the cancer cells and factors proposed by the tumor microenvironment. As a result, a condition termed oncogenic metabolic symbiosis in which components of the tumor microenvironment (TME) promote tumor growth often occurs. Understanding how oncogenic metabolic symbiosis emerges and evolves is crucial for perceiving tumorigenesis. The process by which tumor cells reprogram their TME involves many mechanisms, including changes in intercellular communication, alterations in metabolic phenotypes of TME cells, and rearrangement of the extracellular matrix. It is possible that one molecule with a pleiotropic effect such as Caveolin-1 may affect many of these pathways. Here, we discuss the significance of Caveolin-1 in establishing metabolic symbiosis in TME.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020055
003      
CZ-PrNML
005      
20210830101648.0
007      
ta
008      
210728s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ijc.32987 $2 doi
035    __
$a (PubMed)32196654
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Raudenska, Martina $u Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a Caveolin-1 in oncogenic metabolic symbiosis / $c M. Raudenska, J. Gumulec, J. Balvan, M. Masarik
520    9_
$a Metabolic phenotypes of cancer cells are heterogeneous and flexible as a tumor mass is a hurriedly evolving system capable of constant adaptation to oxygen and nutrient availability. The exact type of cancer metabolism arises from the combined effects of factors intrinsic to the cancer cells and factors proposed by the tumor microenvironment. As a result, a condition termed oncogenic metabolic symbiosis in which components of the tumor microenvironment (TME) promote tumor growth often occurs. Understanding how oncogenic metabolic symbiosis emerges and evolves is crucial for perceiving tumorigenesis. The process by which tumor cells reprogram their TME involves many mechanisms, including changes in intercellular communication, alterations in metabolic phenotypes of TME cells, and rearrangement of the extracellular matrix. It is possible that one molecule with a pleiotropic effect such as Caveolin-1 may affect many of these pathways. Here, we discuss the significance of Caveolin-1 in establishing metabolic symbiosis in TME.
650    _2
$a kaveolin 1 $x metabolismus $7 D051242
650    _2
$a mezibuněčná komunikace $7 D002450
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a nádory $x metabolismus $7 D009369
650    _2
$a symbióza $7 D013559
650    _2
$a nádorové mikroprostředí $7 D059016
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Gumulec, Jaromir $u Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czech Republic
700    1_
$a Balvan, Jan $u Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czech Republic
700    1_
$a Masarik, Michal $u Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u BIOCEV, First Faculty of Medicine, Charles University, Vestec, Czech Republic
773    0_
$w MED00002298 $t International journal of cancer $x 1097-0215 $g Roč. 147, č. 7 (2020), s. 1793-1807
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32196654 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101648 $b ABA008
999    __
$a ok $b bmc $g 1690777 $s 1140501
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 147 $c 7 $d 1793-1807 $e 20200421 $i 1097-0215 $m International journal of cancer $n Int J Cancer $x MED00002298
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options